President, Daicel Arbor Biosciences and Daicel Chiral Technologies
Ravi joined the company in July 2022 as President, Daicel Arbor Biosciences, with his role expanding in April 2023 to include the role of President, Daicel Chiral Technologies. Ravi brings over twenty years of diverse international experience in both start-ups and large global businesses in the life science and biotechnology industries. Prior to joining Daicel Arbor Biosciences, Ravi served as Director, Strategy & Business Development with Thermo Fisher Scientific’s Genetics Science Division.
With a passion for applying technologies to create innovative solutions, Ravi has held business and functional leadership roles at Life Technologies (now part of Thermo Fisher), Perkin Elmer, DuPont, Pioneer (now Corteva Agriscience) and Monsanto (now Bayer).
Ravi received his Master of Business Administration (M.B.A.) from Whitman School of Management, Syracuse University, and his Bachelor of Science from Rutgers University.
Chief Financial Officer
Lynda became Chief Financial Officer of Daicel Arbor Biosciences with the acquisition by Chiral Technologies in 2019. She holds this title concurrently with both companies, having been with Chiral in this leadership role since 2017. Lynda has a wealth of knowledge and experience in finance and accounting within businesses of various sizes and across multiple industries, public and private. Her experience includes working on acquisitions, divestures, private equity and IPOs. Lynda played an instrumental role in the due diligence, acquisition and integration of Daicel Arbor Biosciences. She earned a B.S. degree in Accounting from Susquehanna University, where she graduated summa cum laude.
Vice President, Sales and Marketing
Lisa serves as Vice President of Sales and Marketing for both Chiral Technologies and Daicel Arbor Biosciences. In this global leadership role, she is responsible for developing creative strategies to achieve company growth and ensure customer satisfaction, helping to drive the development of the organization to support these objectives. Lisa joined Chiral Technologies in 2003 as Sales Manager for the New England states, then later became Director of Sales for Northeastern and Western USA, along with distributor regions in North and South America. She was instrumental in helping the company expand sales activities beyond the traditional core products, and in aligning marketing efforts with established sales goals.
Jean-Marie Rouillard, Ph.D.
Director of Technology
Dr. Rouillard co-founded Biodiscovery LLC (doing business as Daicel Arbor Biosciences) in 2006 with Dr. Erdogan Gulari after spending time as a research investigator in Dr. Gulari’s lab at the University of Michigan. He has a vast amount of experience in developing molecular biology technologies, custom DNA microarray synthesizers, devices for embedded molecular biology processes, and bioinformatics pipelines, which form the foundation of technologies provided by Daicel Arbor Biosciences. He earned his Ph.D. at University Pierre and Marie Curie in Paris and has collaborated with thought leaders in genetics and synthetic biology to deliver innovative solutions for complex research questions.
Alison Devault, Ph.D.
Director of Product Management
Alison joined Daicel Arbor Biosciences (then, MYcroarray) in 2014 as Product Manager for myBaits hybridization capture kits and was promoted to Director of Genomics in 2019. She has helped guide the significant expansion of Daicel Arbor’s next-generation sequencing portfolio, focusing on specialty genomics products and services that leverage Daicel Arbor’s novel oligo synthesis technology and expertise in solving complex genomics challenges. Prior to her work at Daicel Arbor, Alison completed her doctoral research with the McMaster University Ancient DNA Centre, applying novel next-generation sequencing techniques to the study of ancient pathogen DNA.
Joseph Barendt, Ph.D.
Senior Director, International Business Development
Daicel Life Sciences SBU
Joe Barendt was appointed CEO of Chiral Technologies in 2006, and named President in 2016. He then led the movement of the company into genomics with several acquisitions, most notably that of Arbor Biosciences in 2019. Upon the successful integration and consolidation of the acquisitions, Joe was made President of the Daicel Arbor Biosciences subsidiary. In 2023 he joined Daicel Life Sciences SBU as Senior Director, International Business Development, and became Executive Vice President of Chiral Technologies, where he remains as a Board Member. Prior to starting his career with Daicel and Chiral Technologies, Joe held executive leadership positions in the life sciences and chemical industries, including Callery Chemical Company, Reheis/GenTek, and Gabriel Performance Products. Joe earned his Ph.D. in Chemistry at the University of Colorado, and his Executive MBA at The Katz School of Business, University of Pittsburgh.
Jacob Enk, Ph.D.
Director of Research, Development,
Jake specializes in the design and evaluation of molecular tools for targeted sequencing, and as the Director of Research, Development, and Applications for Daicel Arbor Biosciences, he is passionate about matching our clients’ research needs with innovative, cost-effective genomics technologies. Before joining Daicel Arbor Biosciences in 2014, he performed graduate work in zooarchaeology and paleogenetics at Indiana University (B.S.) and the University of Utah (M.S.). Jake earned his Ph.D. from McMaster University under the mentorship of Prof. Hendrik Poinar, where he focused on Pleistocene elephantid phylogeography using ancient DNA techniques.
President, CPI (PharmaTek)
Tatsushi Murakami has dedicated his career to the Life Sciences area with over 30 years of experience. He has been a board member of Chiral Technologies since 2016, and was deeply involved in the acquisition of Arbor Biosciences. His initial role as a research scientist in Chiral Chromatography at Daicel, Japan, was followed by global experience, including 5 years working in France. After a successful career in developing the technology and sales organization for the core business, Tatsushi was promoted to President of CPI (PharmaTek) in 2021, where he leads a global team with operations reporting to him from Japan, China, India, Europe, and the US. His industrial experience spans pharmaceutical, fine chemicals, genomics, and academia, and he completed graduate school at Kyoto University. He believes that our potential for a bright future is enabled by close collaboration and highly-engaged discussion among our global teams.
President, Daicel America Holdings
Takayuki Asano has been a board member of Chiral Technologies since 2020, shortly after the acquisition of Arbor Biosciences by Chiral Technologies. He provides ongoing support and advice to both Arbor and Chiral through his active board participation. As the President & CEO of Daicel America Holdings, he manages the regional holding company of Daicel Corporation in the United States and is responsible for maintaining and growing the business portfolio of the Daicel Group in North America. Takayuki has been with Daicel Corporation for over 25 years and has held managerial positions in chemical marketing, procurement, new business development, and business planning within Daicel Group companies. Takayuki earned a Master degree in Polymer Science from the Kyoto Institute of Technology.
Executive Officer, Life Science Business Division, Daicel
Seiji Sakano is an executive officer of Daicel Corporation and general manager of the Life Sciences SBU (Strategic Business Unit). Seiji joined Daicel to lead the Life Sciences business in 2021. Prior to joining Daicel, he worked in Asahi Kasei Corporation for 30 years, starting as a research scientist and working his way through positions such as corporation venture investment, M&A project leader of ZOLL Medical Corporation, and then the founder of Asahi Kasei ZOLL Medical, a Japanese subsidiary of ZOLL. Seiji was ultimately named President of ZOLL Medical in 2012 where he worked to build the company into a $25 million business with double-digit CAGR. Upon joining Daicel, Seiji was added to Chiral Technologies Board of Directors, where he provides relevant advice from his broad experience in the life sciences industry. He completed graduate courses at the University of Nagoya, and earned his Ph.D. from the University of Kumamoto. Seiji has published 40 peer-reviewed scientific papers and over 30 patent applications, including IPO and US patents awarded.